Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

In a rising market, two companies stood out on the downside.

Will This Stock's Pain Be Medicare's Gain?

Shares of Biogen Inc fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial treatment that was approved last year.

Biogen slumps after Medicare's restrictive decision on Alzheimer's drug

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.  However, the decision only extends to patients in a qualifying clinical trial.

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply

Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer's drug whose benefits have been widely questioned, a major development in the nation's tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

Medicare limits coverage of Biogen's $28,000-a-year Alzheimer's drug

Doctors demanded the FDA revoke its approval for the Alzheimer's drug Aduhelm, which can cause side effects like brain bleeding.

Medicare Seeks To Limit Coverage For Controversial Alzheimer's Drug Aduhelm

The guidance is a blow for Biogen, which has struggled with sales of its new drug after a controversial FDA approval.

Medicare proposes limiting coverage of controversial Alzheimer's drug to people involved in clinical trials

Biogen Inc. BIIB, +2.64% shares fell more than 6% in the extended session Tuesday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said it plans to cover the biotech's controversial Alzheimer's drug Aduhelm and future others like it only in certain instances. CMS's proposal is that Food and Drug Administration-approved monoclonal antibodies such as Aduhelm and others in its class would be covered for people with Medicare only if they are enrolled in "qualifying clinical trials," the agency said.

Biogen stock falls more than 6% after Medicare plans coverage limits for pricy Alzheimer's drug

Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.

Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drug

Biogen Inc. (BIIB) CEO Michel Vounatsos on JPMorgan 40th Annual Healthcare Conference (Transcript)

Biogen investors are eagerly awaiting guidance about whether and how Medicare will cover the drugmaker's Alzheimer's disease therapy, Aduhelm.

Biogen's Alzheimer's Drug Has Another Shot at Success

Vertex Pharmaceuticals

In this battle of biotech giants, one emerges as the clear winner.

Better Buy: Vertex Pharmaceuticals vs. Biogen

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis

AbbVie

Bristol-Myers

Hoth Therapeutics

Johnson & Johnson

Longeveron

Pfizer

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

These Emerging Biotechs Could Beat Alzheimer's Disease

Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.

Why Biogen's Alzheimer's drug Aduhelm is so controversial

Ionis Pharma

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

Federal officials are struggling with a decision that could determine the future of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, and whether significant numbers of patients use it. In January, Medicare plans to issue a preliminary decision on covering the expensive medication, reports New York Times.

Medicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT

Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.

Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung

Samsung's biotech division disputed the report in a filing in South Korea, calling it "not true," according to a translated version.

Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker

Vector Group

There are solid reasons why these companies don't appear to be participating in the market rally.

Don't Panic About These 2 Stocks' Falling Prices on Thursday

Adaptimmune Therapeutics

Alnylam Pharmaceuticals

BioMarin Pharmaceutical

CRISPR Therapeutics

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

4 Biotechs That Could Be Potential Takeover Targets in 2022

Biogen BIIB, +9.46% shares slumped 5% in early premarket action after Samsung Biologics 207940, +1.46% called a media report it was about to buy the U.S. company "not true." The brief statement didn't elaborate on what was inaccurate about the Korean Economic Daily report which said Biogen could be purchased for about $42 billion, which boosted the Alzheimer drug maker stock by 9% on Wednesday.

Biogen shares slump after Samsung Biologics denial of buyout report

Shares of Biogen surged Wednesday following a report that South Korean giant Samsung Group is in talks to acquire the US biotech company for more than $40 billion.

Samsung in talks to buy Biogen for $42 bn: report

Biogen, which owns nearly half of a Samsung unit, shares surged Wednesday. A South Korean newspaper reported that Samsung wants to buy Biogen for as much as $42 billion.

Samsung Denies Report That It Wants to Buy Biogen

The rumor mill is grinding hard with the company, which, according to a newspaper report, is in talks to be acquired.

News for Biogen Stock (BIIB)